Antibody Drug Conjugates (ADCs) have been a game-changer in precision oncology over the past 25 years. Originally a bold concept, ADCs have now become a cornerstone in treating both blood cancers and solid tumors. The latest generation of ADCs features advanced technologies like smarter linkers, novel payloads, and higher drug-antibody ratios, pushing the boundaries of […]
Category: antibody drug conjugates (adcs)
Daiichi Sankyo’s Future with ADC Cancer Drugs
Daiichi Sankyo’s ADC cancer drug, Enhertu, generated $3.7 billion in sales and is meeting expectations. However, challenges lie ahead for Datroway and the lead program with Merck. Despite U.S. approval for Datroway, Daiichi Sankyo faces hurdles in lung cancer development due to mixed study results and a recent setback with Merck on another ADC application. […]
ADCs Impact on NSCLC Market Growth
Antibody drug conjugates (ADCs) are projected to dominate the $3.9 billion NSCLC market by 2032. Despite a historical lack of ADC presence in NSCLC, recent approvals like AstraZeneca and Daiichi Sankyo’s Enhertu signify a turning point in targeting HER2-mutated tumors. Read more about this — thepharmaletter.com
